Peter Würz

Helsinki, Finland

Monday 27 May 15:45

METABOLOMIC CONSEQUENCES OF PCSK9 INHIBITION COMPARED WITH STATIN THERAPY

Late Breaking session on pharmacology of dyslipidemia